Biogen (BIIB) Cash from Operations (2009 - 2026)

Biogen has reported Cash from Operations for 18 years, with the latest figure at $448.9 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 178.99% year-over-year to $448.9 million in Q2 2026; TTM through Jun 2026 was $2.9 billion, a 36.0% increase from a year earlier, with the FY2025 full-year figure at $2.2 billion, down 23.33% from the prior year.
• Cash from Operations was $448.9 million for Q2 2026 at Biogen, down from $645.5 million in the prior quarter.
• The five-year high for Cash from Operations was $1.3 billion in Q3 2025, with the low at -$175.0 million in Q4 2022.
• Average Cash from Operations over 5 years is $505.9 million, with a median of $532.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 120.88% in 2022, then jumped 5987.2% in 2024.
• Over 5 years, Cash from Operations stood at -$175.0 million in 2022, then soared by 107.14% to $12.5 million in 2023, then surged by 5987.2% to $760.9 million in 2024, then sank by 32.72% to $511.9 million in 2025, then retreated by 12.31% to $448.9 million in 2026.
• The last three Cash from Operations figures came in at $448.9 million (Q2 2026), $645.5 million (Q1 2026), and $511.9 million (Q4 2025), per Business Quant data.